

SSI improvement programme meeting

Surgical site infection (SSI) investigation quarterly review

28 July 2022

Surgical Site Infection Improvement Programme

Opening karakia

E te huinga Whāia te mātauranga, kia mārama Unuhia te anipā, te nguha, kia mahea Kia whai take ngā mahi katoa Tū māia, tū kaha Aroha atu, aroha mai Tātou i a tātou katoa Hui e tāiki e

For this gathering seek knowledge, for understanding draw out the anxiety and uncertainty, clear it away have purpose in all that you do stand tall, be strong let us show respect for each other. It is complete

Agenda

Welcome and introductions Opening karakia	Nikki Nikki
The SSI investigation process	Amanda Michelle
Case study	Ruth
Trends in SSI	Ruth
Evidence for staphylococcus decolonisation	Arthur
Update to online resources	Ruth
Closing karakia	Nikki

SSI investigation process for light surveillance

 Districts that have moved to light surveillance are required to undertake a detailed review of orthopaedic SSIs, prioritising deep and organ-space infections

lient Information 11: ander: D.M. D.	F Other	_		Insert pade here if an	nt sticker vallable.	
ate of birth:						
and a second second	a devide bi	60	DYON			
Mas the patient seen/phone	ed by pre-admiss					
dinicistal?? Date of admission (for sur)						
Date of admission (value)				_		
Date of discharge: Date of death (if applicable	ia):		-1			
Date of death (it sport						
Date of re-admission: Transfer from another a	sute care hospital	7	DAP			
and the second s	stay (pryribry our		-			
Pre-operative length of Postoperative length of	stay (primary add	mission):				
Postoperative lenger of				C Organ	ADDICO.	Not stated
Infection details	Superficial	De	ep	L organ	3	
Type of ball			2		1-	
Organisms identified:	-		Date SSI o by surgical	i team:		
Date S91 symptoms identified:			SAC ratin		010	2 0 3 0 4
ACC treatment claims process initiated?	DYDNOU	nknown	SACING			
and a second sec						

SSI investigation process for light surveillance

 We recommend that superficial SSIs that lead to readmission or further treatment are also investigated

Ient Information	F Other	-	hisert path here it a	ent sticker vallable.			
ate of birth:					-		
dmission/discharge Vas the patient seen/phone	ed by pre-admission	DYD	3N				
A DESCRIPTION OF THE OWNER OF THE		-1-1					
Date of admission (for surg	pary).	-					
Date of discharge:		-	1				
Date of death (if applicable	ie):	-					
Date of re-admission: Transfer from another at		0	YEN				
Transfer from anome of Pre-operative length of Postoperative length of Infection details	stay (primary administ	C Deep	C Organ	space 3	Not stated		
10.01		2	SSI confirmed				
Type of 591;	1	Dete	rgical team:	-	2 0 3 0 4		
Type of S31: Organisms identified:		by 80			S Clara		
Type of 591;		ph an	nating:	010			
Type of S3: Organisms identified: Date S9I symptoms		ph an		010			

SSI investigation process for light surveillance

 For those who have continued with full surveillance, use of the SSI investigation tool is optional but encouraged

ent Informat				hisert pad here if a	ent söcker wallable.			
nder:	10-1-							
te of birth:	-							
dmission/dla	charge	ed by pre-admiss	ion	DYDN				
ras the patien Intoletall?	A PERIADar			11				
Date of admis	sion (for sun	gery).						
Date of disch				11				
Date of deat	h ilf applicab	in)i		11				
	mission:			DYDN				
	manifest 7	oute care hospital	17	Lite.				
and the owner of the	in the set	stay (prymbry our		-				
Pre-operat	two ionath of	stay (primary ad	mission).					
Intection	details			C Orga	space INot stated			
		Superficial	00	ep Log	3			
Type of S	291;			2				
Organist	ns identified:			Date SSI confirmed by surgical team:				
Date 59 Identifie	l symptoms			BAC rating:	01020304			
ACC to	eatment process			SACING				
initiate	87							

SSI champion responsibilities

- 1. Complete the SSI investigation at any time using the Commission's SSI investigation tool
- 2. Summarise the SSI investigations on the Commission's quarterly Excel summary report sheet

Completing the quarterly SSI summary report

Key fields

- 1. National monitor form ID (this is not the NHI)
- 2. Date of SSI
- 3. Procedure type
- 4. Type of infection
- 5. Key findings
- 6. Key action points



Example of a quarterly report

Surgical site infection investigation form quarterly summary DHB Select from drop down list Please select Date/Quarter Dec 21-Mar 22 National Monitor Procedure Type of Form ID Date of SSI infection Key findings Key action points Case Type ASA 3, smoker, hx peripheral ulcers Follow up why anti-staph bundle not 6-Feb-22 Knee anti-staph bundle not completed completed Case 1 Deep XXXX Follow up why anti-staph bundle not smoker, IVDU, ASA 3 Case 2 20/02/22 Hip anti-staph bundle not completed completed XXXX Deep ASA 3, High BMI Follow up why anti-staph bundle not Case 5 28/02/22 Knee revision Superficial anti-staph bundle not completed completed XXXX

Using the SSI investigation form in ICNet

Michelle Taylor to demonstrate



Submitting the quarterly summary report

 Submit quarterly summary reports on 1 April, 1 July, 1 October and 1 January

Submitting the quarterly summary report

 Submit data on SSIs investigated in the three months before the meeting, eg, for July, submit infections investigated in April, May or June

Submitting the quarterly summary report

 Meetings to discuss the findings of these summary reports are held in April, July, October and January to monitor trends and discuss actions and quality improvement measures with peers.

Resources

- Visit the IPC light surveillance web page on the Commission website
 - tool, forms and resources
- New 'A guide to implementing light surveillance for the orthopaedic SSIIP'
- Contact us on: SSIIP@hqsc.govt.nz

Home > Our work > Infection prevention and control > Our programmes Surgical site infection improvement programme (SSIIP) > Surgical site infections > Light surveillance

Mātai ā-rama Light surveillance

The orthopaedic Surgical Site Infection Improvement Programme (SSIIP) has been a successful national programme since 2011. Collection of data started in 2013 with the median national rate of orthopaedic surgical site infections (SSIs) decreasing by 25 percent by August 2015. Compliance with the recommended evidence-based interventions (surgical antibiotic prophylaxis and skin preparation) has been sustained at a high rate since this decrease in SSI rate.

In July 2019, the Commission released a discussion paper seeking feedback about proposed changes to data collection requirements for orthopaedic procedures and options for inclusion of other procedures. This was in response to recommendations made by an external evaluation of the SSIIP programme in which the feedback from the sector was a preference to reduce time spent on data collection and to have more time to identify contributing factors of the SSI cases.

At its February 2020 meeting the Commission's Board approved the option for DHBs to transition to light surveillance for the orthopaedic SSIIP. Light surveillance requires all data collection fields to be completed for SSI cases only rather than for all procedures, which now only need 10 fields of data recorded. This will significantly reduce the time spent on data collection. Health Districts can choose to maintain full surveillance (status quo) or transition to light surveillance.

Districts that move to a 'light surveillance' method need to undertake a more detailed review on the deep and organ space SSIs. The 'surgical site infection (SSI) investigation tool' should be used to complete a detailed review of cases. To assist with these investigations, a summary of practice points related to an SSI investigation has been provided by Dr Arthur Morris, Clinical lead for the SSIIP. Each guarter a summary report of SSI cases must be submitted to the Commission.

For details on undertaking light surveillance, including instructions on how to create and upload a CSV data file, refer to the light surveillance implementation guide or email us at SSIIP@hqsc.govt.nz.

Related resources

- Resource: A guide to implementing light surveillance for the orthopaedic SSIIP
- Resource: Discussion paper: proposal to change data collection requirements for orthopaedic procedures and options for inclusion of other procedures (feedback closed)
- Resource: Surgical site infection SSI investigation tool
- · Resource: Using the Health Quality & Safety Commission Surgical Site Infection investigation tool a summary of practice points from Dr Arthur Morris, clinical lead, Health Ouality & Safety Commission
- Resource: SSIIP investigation form quarterly summary

Case study

- 70-year-old man
- Superficial SSI following revision of left total knee replacement
 - Discharged day 3 after surgery
 - Readmitted 11 days post-op with signs and symptoms of infection
 - SSI confirmed 7 days after readmission by surgical team
- Staphylococcus aureus



SSI risk factors

Patient risk factors prior to surgery	(Indicates increased risk)	(Indicates neutral risk)	
Revision surgery:	⊠ Y		Unknown
Prior infection in joint:	□ Y	⊠ N	Unknown
ASA score > 2 ASA score: 3	⊠ Y		Unknown
Infection at distal sites at time of surgery: Site(s):	ΩY	⊠ N	Unknown
Age > 60 years:	⊠ Y		Unknown
Diabetes type I/IDDM:	□ Y	⊠ N	Unknown
Diabetes type II/NIDDM:	□ Y	⊠ N	Unknown
HbA1c ≥ 7% prior to surgery:	□ Y	⊠ N	Unknown
Patient smokes (within 1 month prior to surgery):	□ Y	⊠ N	Unknown
Obesity – BMI > 30: □ 30–34.9 □ 35–40 ⊠ > 40	×Ν	□ N	Unknown
S aureus colonisation	□ Y	⊠ N	Unknown
Skin condition – active or poorly controlled:	□ Y	⊠N	Unknown
Immunosuppression (eg, steroids, cytotoxic drugs):	□ Y	N	Unknown
Any other risk factors identified? If yes, was there a specific plan put in place, eg, referral, deferment of surgery? \Box Y \Box N Describe:	□ Y	⊠N	Unknown

ASA, American Society of Anaesthesiologists; BMI, body mass index; IDDM, insulin-dependent diabetes mellitus; MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*; NIDDM, non-insulin-dependent diabetes mellitus.

SSI risk factors

- Revision surgery
- ASA score of 3
- Age >60 years
- BMI >40



Risk factors not identified

No problems identified with:

- procedure
- post-op clinical management, eg, oxygen saturation, blood loss, etc.
- wound management prior to discharge
- discharge process (given written wound instructions and discharged to own home).

S. aureus factors

- Nil S. aureus colonisation before surgery
- No compliance with nasal or skin decolonisation doses
- But S. aureus infection

SSI summary findings

Pre-operative anti-staphylococcal decolonisation

- Not documented
- Not used/given

Pre-operative anti-staphylococcal bundle							
Skin decolonisation compliance:	□ No bundle	□ Full (all doses)	□ Partial (some doses)	□ None (no doses)	□ N/A (skin not part of bundle)	□ Unknown (not documented)	
Nasal decolonisation compliance:	□ No bundle	□ Full (all doses)	□ Partial (some doses)	□ None (no doses)	□ N/A (nasal not part of bundle)	 Unknown (not documented) 	

Quality improvement

Problem

- Staphylococcal decolonisation information not completed in theatre/post-anaesthetic care unit (PACU)
- Change to electronic forms

Action

 Infection prevention and control (IPC) work with PACU to ensure bundle compliance information is captured



Group discussion point

- How does your district capture *S. aureus* decolonisation data?
- Does this work?
- If not, why not?
- How could it be improved?





Systematic review and meta-analysis of *S. aureus* SSI prevention in orthopaedic and cardiac surgery

> Dr Arthur Morris, Clinical lead (presentation available on request from ssiip@hqsc.govt.nz)



Website resources – update



Light surveillance guide



Mātai ā-rama Light surveillance

The orthopaedic Surgical Site Infection Improvement Programme (SSIIP) has been a successful national programme since 2011. Collection of data started in 2013 with the median national rate of orthopaedic surgical site infections (SSIs) decreasing by 25 percent by August 2015. Compliance with the recommended evidence-based interventions (surgical antibiotic prophylaxis and skin preparation) has been sustained at a high rate since this decrease in SSI rate.

In July 2019, the Commission released a <u>discussion paper</u> seeking feedback about proposed changes to data collection requirements for orthopaedic procedures and options for inclusion of other procedures. This was in response to recommendations made by an external evaluation of the SSIIP programme in which the feedback from the sector was a preference to reduce time spent on data collection and to have more time to identify contributing factors of the SSI cases.

At its February 2020 meeting the Commission's Board approved the option for DHBs to transition to light surveillance for the orthopaedic SSIIP. Light surveillance requires all data collection fields to be completed for SSI cases only rather than for all procedures, which now only need 10 fields of data recorded. This will significantly reduce the time spent on data collection. Health Districts can choose to maintain full surveillance (status quo) or transition to light surveillance.

Districts that move to a 'light surveillance' method need to undertake a more detailed review on the deep and organ space SSIs. The 'surgical site infection (SSI) investigation tool' should be used to complete a detailed review of cases. To assist with these investigations, a summary of practice points related to an SSI investigation has been provided by Dr Arthur Morris, Clinical lead for the SSIIP. Each quarter a summary report of SSI cases must be submitted to the Commission.

efer to

For details on undertaking light surveillance, including instructions on how to create and upload a CSV the light surveillance implementation guide or email us at SSIIP@hqsc.govt.nz.

Related resources

- · Resource: A guide to implementing light surveillance for the orthopaedic SSIIP
- · Resource: Discussion paper: proposal to change data collection requirements for orthopaedic procedures and options

A guide to implementing light surveillance for the orthopaedic SSIIP

18th July, 2022 Infection prevention and control Multimedia

This document outlines the process for undertaking 'light surveillance' for the orthopaedic SSIIP. It supplements the Orthopaedic surgery implementation manual.

Contact the Health Quality & Safety Commission (the Commission) at <u>SSIIP@hqsc.govt.nz</u> if you would like to discuss changing to light surveillance. The IPC team can support you with the transition and determine the start date for your organisation.

Attachments

A guide to implementing light surveillance for the orthopaedic SSIIP - July 2022

PDF | 288 KB

A guide to implementing light surveillance for the orthopaedic SSIIP - July 2022

DOCX | 407 KB

SSI orthopaedic dashboard by Health Quality & Safety Commission

Process and outcome measures Risk factor summary – Full sur... Risk factor summary – Light s... Risk factor analysis SSI orthopaedic equity

Definitions and resources

Accessing resources from the Resources Orthopaedic implementation dashboard manual FAQs 🔻 < Process and outcome measures Risk factor summary – Full sur.,, Risk factor summary – Light s.,, Risk factor analysis SSI orthopaedic equity Definitions and resources Definitions and resources Resources Orthopaedic VLAD report Surgical antimicrobial prophylaxis intervention guidelines Orthopaedic implementation Correct antimicrobial choice and dose manual SSI investigation tool First line of choice for adult orthopaedic surgery is a ≥ 2g dose of cefazolin. A ≥ 1.5g dose of cefuroxime is an acceptable alternative (since Q1, 2015). The QSM compliance target for correct antimicrobial choice and dose is 95%. Clindamycin (600mg) or vancomycin (1g up to 70kg and then 15mg/kg for patients weighing more than 70kg, to a maximum of 2g) should be reserved as alternative agents in the event of allergy to β-lactam agents. Correct antimicrobial timing Antimicrobial prophylaxis is administered as a single dose 0 to 60 minutes before knife to skin (KTS). Anti-staph bundle The QSM compliance target for correct antimicrobial timing is 100% for primary procedures In most revision procedures, prophylaxis should be given 'on time', ie, 0-60 minutes before KTS. If the second side of a bilateral procedure is commenced more than an hour after the initial dose of prophylaxis a second dose is required to provide the second side Orthopaedic VLAD report with the same level of protection as the first. If vancomvcin has been used no second dose is required. Patient education brochure Correct antimicrobial duration Antimicrobial prophylaxis is discontinued within 24 hours after surgery end time. Three doses of cefazolin or cefuroxime administered eight hours post-operatively is accepted as discontinuation within 24 hours of surgery. Exposure to antimicrobials is associated with a greater risk of subsequent colonisation with resistant organisms. SSI investigation tool Skin antisepsis preparation intervention guidelines Patient education video An alcohol based antiseptic solution (at least 70%) containing either chlorhexidine gluconate or povidone-iodine antiseptic is used to prepare the incision area for all procedures. Alcohol based chlorhexidine and povidone-iodine antiseptic solutions significantly reduce the likelihood of surgical site colonisation and maximise the rapidity, potency and duration of bactericidal activity when compared to other solutions. Anti-staph bundle Data collected for this intervention is no longer reported as a QSM (from 1 July 2016) due to consistent high compliance, however DHBs continue to collect, analyse and report on this data. Other resources Definitions for infection The definitions of SSI being utilised for this project are those utilised by The National Healthcare Safety Network (CDC, 2018). Patient education brochure For further information on the definitions for SSI refer to the orthopaedic surgery implementation manual. Superficial SSI occurs within 30 days after the procedure (day 1 = day of procedure). Journal articles Deep and organ/space SSI occurs within 90 days after the procedure (day 1 = day of procedure).

Conclusion

- Questions?
- Comments?
- Next meeting

Request for SSI scenarios

Please submit scenarios for orthopaedic or cardiac SSIs that could be used for future training to:

SSIIP@hqsc.govt.nz

Closing karakia

Kua mutu a tātou mahi Ka tae te wā mō te whakairi te kete I te kete kõrero, I te kete whakaaro Hei tiki atu anō mā tatou Tauwhirotia mai mātou katoa Ō mātou hoa Ō mātou whānau Aio ki te Aorangi. Hui e tāiki e.

Our work has finished the time has arrived to gather one's thoughts in the basket that contains discussion and concepts that we may use it again in the future Protect us all our colleagues our families Peace to the universe. It is complete.